Showing 1 – 4 of 4
Relevance | Newest | Oldest |
  • Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial

    Abstract Full Text
    is active quiz has multimedia
    JAMA. 2024; 331(17):1460-1470. 10.1001/jama.2024.4011

    This secondary analysis of a randomized clinical trial assesses whether screening for prostate-specific antigen reduces prostate cancer mortality at 15-year follow-up.

  • Prostate-Specific Antigen Testing for Prostate Cancer Screening—Is the Message Getting Through?

    Abstract Full Text
    JAMA Oncol. 2021; 8(1):47-49. 10.1001/jamaoncol.2021.5129
  • Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial

    Abstract Full Text
    free access
    JAMA. 2018; 319(9):883-895. 10.1001/jama.2018.0154

    This cluster randomized trial evaluates the effect of a single prostate-specific antigen (PSA) screening test on 10-year prostate cancer–specific mortality among men aged 50 to 69 years treated at UK primary care practices.

  • Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer: Helping Decision Making for Patients and Their Physicians

    Abstract Full Text
    JAMA. 2017; 317(11):1121-1123. 10.1001/jama.2017.1703